Financial Performance - OnKure reported approximately $110.8 million in cash and cash equivalents as of December 31, 2024, an increase from $29.9 million in 2023[5][15]. - The net loss for Q4 2024 was $17.4 million, or $1.37 per share, compared to a net loss of $9.5 million, or $30.14 per share, in Q4 2023[7][16]. - Total operating expenses for the year ended December 31, 2024, were $54.4 million, compared to $36.9 million in 2023, representing a 47.2% increase[16]. Research and Development - Research and development (R&D) expenses for Q4 2024 were $14.4 million, up from $8.8 million in Q4 2023, reflecting a 63.6% increase[5][16]. - OnKure has completed patient enrollment in the Part A monotherapy arm of the PIKture-01 trial, with no dose limiting toxicities observed[4]. - The company initiated patient dosing in Part B of the PIKture-01 trial in Q4 2024, evaluating OKI-219 in combination with fulvestrant[8]. Administrative Expenses - General and Administrative (G&A) expenses rose to $4.3 million in Q4 2024, compared to $1.1 million in Q4 2023, marking a 290.9% increase[6][16]. Future Plans and Updates - OnKure expects to provide a clinical update on the PIKture-01 trial in the second half of 2025, with additional data from the OKI-219 program anticipated[4][3]. - OnKure plans to announce a pan-mutant development candidate in Q2 2025, targeting key mutations with approximately 10-fold selectivity[8]. Mergers and Financing - The merger with Reneo Pharmaceuticals closed on October 4, 2024, along with a $65 million financing[8].
OnKure Therapeutics, Inc.(OKUR) - 2024 Q4 - Annual Results